alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          SEP-30-1997
<PERIOD-END>                               SEP-30-1997
<CASH>                                       1,142,988
<SECURITIES>                                         0
<RECEIVABLES>                                4,205,196
<ALLOWANCES>                                   410,000
<INVENTORY>                                  4,399,426
<CURRENT-ASSETS>                            10,276,081
<PP&E>                                       8,129,393
<DEPRECIATION>                               3,865,092
<TOTAL-ASSETS>                              20,273,748
<CURRENT-LIABILITIES>                        5,352,305
<BONDS>                                      3,595,378
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                    21,589,413
<OTHER-SE>                                     (7,571)
<TOTAL-LIABILITY-AND-EQUITY>                20,273,748
<SALES>                                     20,875,397
<TOTAL-REVENUES>                            20,875,397
<CGS>                                       17,668,774
<TOTAL-COSTS>                               12,236,740
<OTHER-EXPENSES>                             2,210,027
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             361,894
<INCOME-PRETAX>                           (11,498,379)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                       (11,498,379)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                              (11,498,379)
<EPS-PRIMARY>                                   (2.33)
<EPS-DILUTED>                                   (2.33)
        

</TABLE>
<TABLE> <S> <C>

<ARTICLE>                     5
<LEGEND>
This schedule  contains summary financial  information  extracted from financial
statements  for the six month period ended November 30, 1997 and is qualified in
its entirety by reference to such financial statements.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          MAY-31-1998
<PERIOD-END>                               NOV-30-1998
<CASH>                                             885 
<SECURITIES>                                         0 
<RECEIVABLES>                                    4,233 
<ALLOWANCES>                                        62 
<INVENTORY>                                      1,004 
<CURRENT-ASSETS>                                 7,920 
<PP&E>                                           7,608 
<DEPRECIATION>                                  (4,955)
<TOTAL-ASSETS>                                  13,086 
<CURRENT-LIABILITIES>                            7,705 
<BONDS>                                            732 
<PREFERRED-MANDATORY>                                0 
<PREFERRED>                                          0 
<COMMON>                                         5,837 
<OTHER-SE>                                      (2,119)
<TOTAL-LIABILITY-AND-EQUITY>                    13,084 
<SALES>                                              0 
<TOTAL-REVENUES>                                10,650 
<CGS>                                                0 
<TOTAL-COSTS>                                    9,913 
<OTHER-EXPENSES>                                     0 
<LOSS-PROVISION>                                     0 
<INTEREST-EXPENSE>                                 467 
<INCOME-PRETAX>                                    330 
<INCOME-TAX>                                         0 
<INCOME-CONTINUING>                                330 
<DISCONTINUED>                                    (610)
<EXTRAORDINARY>                                      0 
<CHANGES>                                            0 
<NET-INCOME>                                      (280)
<EPS-PRIMARY>                                     (.02)
<EPS-DILUTED>                                     (.02)
                                               

</TABLE>
FIRST DISTRICT COURT OF APPEAL

STATE OF FLORIDA

_____________________________

No. 1D2023-1889

_____________________________

MARIO DANIELS,

Appellant,

v.

STATE OF FLORIDA,

Appellee.

_____________________________

On appeal from the Circuit Court for Leon County.

Joshua Hawkes, Judge.

February 21, 2024

PER CURIAM.

DISMISSED. See Robinson v. State, 255 So. 3d 907 (Fla. 1st 

DCA 2018) (“The order of the circuit court deciding that Appellant 

is not entitled to postconviction discovery is not among the class of 

orders independently appealable by a defendant pursuant to 

Florida Rule of Appellate Procedure 9.140(b)(1).”).

LEWIS, RAY, and KELSEY, JJ., concur.
2

_____________________________

Not final until disposition of any timely and 

authorized motion under Fla. R. App. P. 9.330 or 

9.331.

_____________________________

Mario Daniels, pro se, Appellant.

Ashley Moody, Attorney General, Tallahassee, for Appellee.
EXHIBIT  31.1

Certification  of  Principal  Executive  Officer

I,  Edward  A.  Roth,  Chief  Executive  Officer,  certify  that:

1.   I  have  reviewed  this  quarterly  report  on  Form  10-QSB  of  HairMax
     International,  Inc.

2.   Based  on my knowledge, the report does not contain any untrue statement of
     a  material  fact  or  omit  to state a material fact necessary to make the
     statements  made, in light of the circumstances under which such statements
     were  made,  not  misleading  with  respect  to  the period covered by this
     quarterly  report;

3.   Based  on  my  knowledge,  the  financial  statements,  and other financial
     information  included  in  this  quarterly  report,  fairly  present in all
     material  respects  the financial condition, results of operations and cash
     flows  of  the  registrant  as  of,  and for, the periods presented in this
     quarterly  report;

4.   The  registrant's  other  certifying  officers  and  I  am  responsible for
     establishing and maintaining disclosure controls and procedures (as defined
     in  Exchange  Act  Rules  13a-14  and  15d-14) for the registrant and have:

     a)   designed  such  disclosure  controls  and  procedures  to  ensure that
          material  information  relating  to  the  registrant,  including  its
          consolidated  subsidiaries, is made known to us by others within those
          entities,  particularly  during  the  period  in  which this quarterly
          report  is  being  prepared;

     b)   evaluated  the  effectiveness  of the registrant's disclosure controls
          and procedures as of a date within 90 days prior to the filing date of
          this  annual  report  ("Evaluation  Date");  and

     c)   disclosed  in  this  report  any  change  in the registrant's internal
          control over financial reporting that occurred during the registrant's
          most  recent  quarter  that  has materially affected, or is reasonably
          likely  to  materially  affect, the registrant's internal control over
          financial  reporting;  and;

5.   The  registrant's  other certifying officers and I have disclosed, based on
     our  most  recent  evaluation,  to  the registrant's auditors and the audit
     committee  of  registrant's  board  of directors (or persons performing the
     equivalent  functions):

     a)   all  significant deficiencies and material weaknesses in the design or
          operation  of  internal  control  over  financial  reporting which are
          reasonably  likely  to  adversely  affect  the registrant's ability to
          record,  process,  summarize  and report financial information (all of
          which  do  not  apply);  and

     b)   any  fraud, whether or not material, that involves management or other
          employees  who  have  a  significant role in the registrant's internal
          control  over  financial  reporting,  (all  of  which  do  not apply).



Date:  August  18,  2004



/s/  Edward  A.  Roth
---------------------
Edward  A.  Roth
Chief  Executive  Officer
Exhibit 31.1

CERTIFICATION

I, Kevin M. Tomlinson, Chief Executive Officer of Sport-Haley, Inc., certify that:

1.     I
have reviewed this annual report on Form 10-K of Sport-Haley, Inc.;

2.     Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.     Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.     The
registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) for the registrant and have:



5.     The
registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's
auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):



Date:
October 13, 2004

|/s/KEVIN M. TOMLINSONKevin M. Tomlinson
Chief Executive Officer |  | 
|--------------------------------------------------------------- |  | 

---



QuickLinks
Exhibit 32.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

Pursuant to 18 U.S.C. § 1350, as created by
Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of ImmunoCellular Therapeutics, Ltd. (the Company) hereby certifies that, to his knowledge:

(i) The Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended June 30, 2008 (the Report) fully
complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

|                      |  |  |  |     |  |                     |  |                                                      
|--------------------- |  |  |  | --- |  | ------------------- |  | -----------------------------------------------------
|                      |  |  | 
|Date: August 13, 2008 |  |  |  | By: |  | /s/ C. Kirk Peacock
|                      |  |  |  |     |  |                     |  | C. Kirk Peacock Chief Financial Officer and Treasurer
<PAGE>

                                  Exhibit 23.1

                         Consent of Independent Auditors

We consent to the incorporation by reference in the Registration Statements on
Form S-8 (No. 333-07135 and No. 333-28991) pertaining to the Employee Stock
Purchase Plan, the 1996 Stock Option Plan and 401(k) Salary Reduction Plan and
Trust of Ribozyme Pharmaceuticals, Inc., of our report dated February 9, 2000,
with respect to the financial statements of Ribozyme Pharmaceuticals, Inc.,
included in this Annual Report on Form 10-K for the year ended December 31,
1999.

/s/ERNST & YOUNG LLP
March 1, 2000
II 

111TH CONGRESS 

1ST SESSION S. 2635 

To suspend temporarily the duty on certain surge protective receptacles. 

IN THE SENATE OF THE UNITED STATES 

NOVEMBER 2, 2009 

Mr. SCHUMER (for himself and Mrs. GILLIBRAND) introduced the following 

bill; which was read twice and referred to the Committee on Finance 

A BILL 

To suspend temporarily the duty on certain surge protective 

receptacles. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. CERTAIN SURGE PROTECTIVE RECEPTACLES. 

4 (a) IN GENERAL.—Subchapter II of chapter 99 of 

5 the Harmonized Tariff Schedule of the United States is 

6 amended by inserting in numerical sequence the following 

7 new heading: 

‘‘ 9902.01.00 Duplex surge protection receptacles for a voltage not exceeding 250v alternating current, each with monitor light 

to indicate the device is protecting the circuit (provided 

for in subheading 

8536.30.80) ........................... Free No change No change On or before 

12/31/2011 ’’. 


smartinez on DSKB9S0YB1PROD with BILLS
2 

•S 2635 IS

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies to goods entered, or withdrawn from 

3 warehouse for consumption, on or after the 15th day after 

4 the date of the enactment of this Act. 

Æ 


smartinez on DSKB9S0YB1PROD with BILLS
**EXHIBIT
      32.01**





**Certification
      of Chief Executive Officer Pursuant to 18 U.S.C. Sec. 1350**


**(Section
      906 of the Sarbanes-Oxley Act of 2002)**





Pursuant
      to 18 U.S.C. Sec. 1350, the undersigned officer of Sandston Corporation (the
      "Company") hereby certifies, to such officer's knowledge, that the Company's
      Annual Report on Form 10-KSB for the year ended December 31, 2006 (the "Report")
      fully complies with the requirements of Section 13(a) or 15(d), as applicable,
      of the Securities Exchange Act of 1934 and that the information contained in
      the
      Report fairly presents, in all material respects, the financial condition and
      results of operations of the Company.




/s/
      Daniel J. Dorman





Name:  Daniel
      J.
      Dorman


Title:  President
      and Executive Officer


Date:  March
      5, 2007





The
      foregoing certification (i) accompanies the filing and is being furnished solely
      pursuant to 18 U.S.C. Sec. 1350, (ii) will not be deemed "filed" for purposes
      of
      Section 18 of the Securities Exchange Act of 1934, or otherwise subject to
      the
      liability of that section, and (iii) will not be deemed to be incorporated
      by
      reference into any filing under the Securities Act of 1933 or the Exchange
      Act,
      except to the extent that the small business issuer specifically incorporates
      it
      by reference.




A
      signed
      original of this written statement required by Section 906, or other document
      authenticating, acknowledging, or otherwise adopting the signature that appears
      in typed form within the electronic version of this written statement required
      by Section 906, has been provided to Sandston Corporation and will be retained
      by Sandston Corporation and furnished to the Securities and Exchange Commission
      or its staff upon request.
NOTICE: NOT FOR OFFICIAL PUBLICATION. UNDER ARIZONA RULE OF THE SUPREME COURT 111(c), THIS DECISION IS NOT PRECEDENTIAL AND MAY BE CITED ONLY AS AUTHORIZED BY RULE

.

IN THE 

## A RIZONA 

## C OURT OF 

## A PPEALS

D IVISION O NE

STATE OF ARIZONA , Respondent ,

v. JOSE LUIS CASTELLANOS

- GARCIA , Petitioner

.

N o . 1 CA

- CR 18

- 0266 PRPC

Petition for Review from the Superior Court in Maricopa County

No s

. CR200 0

- 011803 The Honorable Christopher T. Whitten , Judge REVIEW GRANTED; RELI EF DENIED

COUNSEL Maricopa County Attorney’s Office, Phoenix By Diane Meloche Counsel for Respondent
Jose Luis Castellanos

- Garcia , Florence Petitioner

MEMORANDUM DECISION Presiding Judge Kenton D. Jones, Judge Michael J. Brown, and Judge Jon W. Thompson delivered the decision of the Court. FILED 7-24-18STATE v. CASTELLANOS

- GARCIA Decision of the Court

2 P E R C U R I A M : ¶1 Petitioner Jose Castellanos

- Garcia seeks review of the superior court’s order denying his petiti on for post

- conviction relief , filed pursuant to Arizona Rule of Criminal Procedure 32.1. This is the petitioner’s first petition. ¶2 Absent an abuse of discretion or error of law, this Court will not disturb a superior court’s ruling on a petition for post

- conviction relief. State v. Gutierrez , 229 Ariz. 573, 576

- 77, ¶ 19 (2012). It is the petitioner’s burden to show that the superior court abused its discretion in denying the petition. See State v. Poblete , 227 Ariz. 537, 538, ¶ 1 (App. 2011). ¶3 We have reviewed the record in this matter, the superior court’s order denying the petition for post

- conviction relief, and the petition for review. We find that petitioner has not shown any abuse of discretion. ¶4 Accordingly, we grant review and deny re lief.
#### City School District of the City of New York, Appellant, v Colleen McGraham, Respondent.

Submitted December 27, 2010;

decided January 18, 2011

Motion to dismiss appeal denied.
[Federal Register Volume 74, Number 203 (Thursday, October 22, 2009)]
[Notices]
[Page 54589]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-25307]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Request for Comment: National Center for Complementary and 
Alternative Medicine Announcement of Strategic Planning Background 
Papers

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Center for Complementary and Alternative Medicine 
(NCCAM) is developing its third strategic plan and invites the public 
to provide comments on three background papers which will support the 
development of this plan. The papers will cover three topics: Mission, 
priority setting, and communications and decisionmaking. They will be 
publicly available through the NCCAM Web site at from on or about 
October 19 through November 19, 2009. The public is invited to provide 
comments through the NCCAM Web site.
    Background: The National Center for Complementary and Alternative 
Medicine (NCCAM) was established in 1998 with the mission of exploring 
complementary and alternative healing practices in the context of 
rigorous science, training CAM researchers, and disseminating 
authoritative information to the public and professionals.
    To date, NCCAM's efforts to rigorously study CAM, to train CAM 
researchers, and to communicate with the public and professionals, have 
been guided by NCCAM's previous strategic plans, located on the NCCAM 
Web site at http://nccam.nih.gov/about/plans.
    The public is invited to review the background papers and provide 
comments from October 15 through November 15, 2009. The papers may be 
viewed at http://nccam.nih.gov/.
    Request For Comments: The public is invited to provide comments on 
the three background papers that will support the development of 
NCCAM's third strategic plan. Comments may be provided through the 
NCCAM Web site at http://nccam.nih.gov.
    For Further Information: To request more information, visit the 
NCCAM Web site at http://nccam.nih.gov, call 1-888-644-6226, or e-mail 
<<a href="/cdn-cgi/l/email-protection#f9979a98948a89b994989095d7979091d79e968f"><span class="__cf_email__" data-cfemail="eb85888a86989bab868a8287c5858283c58c849d">[email protected]</span></a><ls-thn-eq>
    Comments Due Date: Comments regarding the draft of NCCAM's 
strategic plan are best assured of having their full effect if received 
by November 19, 2009.

    Dated: October 13, 2009.
Jack Killen,
Deputy Director, National Center for Complementary and Alternative 
Medicine, National Institutes of Health.
[FR Doc. E9-25307 Filed 10-21-09; 8:45 am]
BILLING CODE 4140-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
```

[Congressional Bills 111th Congress]
[From the U.S. Government Publishing Office]
[S. 2670 Introduced in Senate (IS)]

111th CONGRESS
  1st Session
                                S. 2670

 To suspend temporarily the duty on 1-(4,6-dimethoxypyrimidin-2-yl)-3-
              [2-(dimethylcarbamoyl)phenylsufamoyl] urea.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                            November 2, 2009

   Mr. Burr introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
 To suspend temporarily the duty on 1-(4,6-dimethoxypyrimidin-2-yl)-3-
              [2-(dimethylcarbamoyl)phenylsufamoyl] urea.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. 1-(4,6-DIMETHOXYPYRIMIDIN-2-YL)-3-[2-
              (DIMETHYLCARBAMOYL)PHENYLSUFAMOYL] UREA.

    (a) In General.--Subchapter II of chapter 99 of the Harmonized 
Tariff Schedule of the United States is amended by inserting in 
numerical sequence the following new heading:

``      9902.01.00       1-(4,6-             Free         No change        No change        On or before 12/ ''.
                          dimethoxypyrimidi                                                  31/2011.......
                          n-2-yl)-3-[2-
                          (dimethylcarbamoy
                          l)phenylsufamoyl]
                          urea (CAS No.
                          213464-778)
                          (provided for in
                          subheading
                          3808.93.15)......

    (b) Effective Date.--The amendment made by subsection (a) applies 
to articles entered, or withdrawn from warehouse for consumption, on or 
after the 15th day after the date of the enactment of this Act.
                                 <all>
```
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED FINANCIAL STATEMENTS OF UTILX CORPORATION FOR THE THREE MONTHS
ENDED JUNE 30, 1998 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH 
FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          MAR-31-1999
<PERIOD-START>                             APR-01-1998
<PERIOD-END>                               JUN-30-1998
<CASH>                                             702
<SECURITIES>                                         0
<RECEIVABLES>                                   18,733
<ALLOWANCES>                                       469
<INVENTORY>                                      8,754
<CURRENT-ASSETS>                                28,332
<PP&E>                                          39,775
<DEPRECIATION>                                  26,557
<TOTAL-ASSETS>                                  42,064
<CURRENT-LIABILITIES>                           14,188
<BONDS>                                          3,022
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            74
<OTHER-SE>                                      24,780
<TOTAL-LIABILITY-AND-EQUITY>                    42,064
<SALES>                                         22,024
<TOTAL-REVENUES>                                22,024
<CGS>                                           19,447
<TOTAL-COSTS>                                   21,865
<OTHER-EXPENSES>                                   135
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 145
<INCOME-PRETAX>                                     24
<INCOME-TAX>                                         8
<INCOME-CONTINUING>                                 16
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                        16
<EPS-PRIMARY>                                     .002
<EPS-DILUTED>                                     .002
        

</TABLE>